Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (471-480 of 649) with videos related to

Pageof 65
Sort By:
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research and Treatment|January 19, 2016
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control studyJoanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2026
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 TrialD Juric, H S Rugo, A Reising, et al.
Breast Cancer Research and Treatment|May 19, 2018
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jacek Gronwald, Henry T Lynch, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Future Oncology (London, England)|August 30, 2022
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline <i>PTEN</i>-inactivating mutationsJordi Rodón, Pauline Funchain, Theodore W Laetsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2010
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsJeff Sperinde, Xueguang Jin, Jayee Banerjee, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast Cancer Research and Treatment|May 5, 2024
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Pageof 65

Showing results (471-480 of 649) with videos related to

Sort By:
Pageof 65
Journal of Experimental & Clinical Cancer Research : CR|November 14, 2023
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Monika Sachet, Cristiano Ramos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Breast Cancer Research and Treatment|January 19, 2016
Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control studyJoanne Kotsopoulos, Tomasz Huzarski, Jacek Gronwald, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2026
Genomic Determinants of Response to Alpelisib Plus Fulvestrant in the SOLAR-1 TrialD Juric, H S Rugo, A Reising, et al.
Breast Cancer Research and Treatment|May 19, 2018
Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jacek Gronwald, Henry T Lynch, et al.
Breast Cancer Research and Treatment|January 25, 2024
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Future Oncology (London, England)|August 30, 2022
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline <i>PTEN</i>-inactivating mutationsJordi Rodón, Pauline Funchain, Theodore W Laetsch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2010
Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patientsJeff Sperinde, Xueguang Jin, Jayee Banerjee, et al.
Breast (Edinburgh, Scotland)|February 22, 2025
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trialsKerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Breast Cancer Research and Treatment|May 5, 2024
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?Kerstin Wimmer, Dominik Hlauschek, Marija Balic, et al.
Pageof 65